Similar articles

• Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis.

  Protogerou AD, Zampeli E, Sfikakis PP. Protogerou AD, et al. Ann Intern Med. 2012 Aug 21;157(4):299-300; author reply 300. doi: 10.7326/0003-4819-157-4-201208210-00019. Ann Intern Med. 2012. PMID: 22910947 No abstract available.
• Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

  Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort Study Group. Bakker MF, et al. Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004. Ann Intern Med. 2012. PMID: 22393128 Clinical Trial.
• Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis.

  [No authors listed] [No authors listed] Ann Intern Med. 2012 Mar 6;156(5):I18. doi: 10.7326/0003-4819-156-5-201203060-00001. Ann Intern Med. 2012. PMID: 22393145 No abstract available.
• [Pharmacotherapy of patients with (early) rheumatoid arthritis].

  Jacobs JW, Blaauw AA, Dijkmans BA, van Riel PL, Bijlsma JW. Jacobs JW, et al. Ned Tijdschr Geneeskd. 2000 Jan 29;144(5):211-6. Ned Tijdschr Geneeskd. 2000. PMID: 10682647 Review. Dutch.
• Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies.

  Jacobs JW. Jacobs JW. Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv27-33. doi: 10.1093/rheumatology/kes084. Rheumatology (Oxford). 2012. PMID: 22685273 Review.